LU92218I2 - Mirabegron ou un de ses sels - Google Patents
Mirabegron ou un de ses selsInfo
- Publication number
- LU92218I2 LU92218I2 LU92218C LU92218C LU92218I2 LU 92218 I2 LU92218 I2 LU 92218I2 LU 92218 C LU92218 C LU 92218C LU 92218 C LU92218 C LU 92218C LU 92218 I2 LU92218 I2 LU 92218I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- bladder
- rat
- urination
- rhythmic
- measurement test
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002323792 | 2002-11-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
LU92218I2 true LU92218I2 (fr) | 2014-01-07 |
LU92218I9 LU92218I9 (fr) | 2019-01-17 |
Family
ID=32310425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU92218C LU92218I2 (fr) | 2002-11-07 | 2013-06-17 | Mirabegron ou un de ses sels |
Country Status (28)
Country | Link |
---|---|
US (5) | US7750029B2 (fr) |
EP (1) | EP1559427B1 (fr) |
JP (1) | JP3815496B2 (fr) |
KR (1) | KR100967070B1 (fr) |
CN (1) | CN100406011C (fr) |
AT (1) | ATE500827T1 (fr) |
AU (1) | AU2003284700B2 (fr) |
BE (1) | BE2013C040I2 (fr) |
BR (1) | BR0316080A (fr) |
CA (1) | CA2503570C (fr) |
CY (2) | CY1111399T1 (fr) |
DE (1) | DE60336334D1 (fr) |
DK (1) | DK1559427T3 (fr) |
ES (1) | ES2360353T3 (fr) |
FR (1) | FR13C0032I2 (fr) |
HU (1) | HUS1300027I1 (fr) |
IL (1) | IL168121A (fr) |
LU (1) | LU92218I2 (fr) |
MX (1) | MXPA05004925A (fr) |
NL (1) | NL300599I2 (fr) |
NO (2) | NO334948B1 (fr) |
NZ (1) | NZ539577A (fr) |
PL (1) | PL211687B1 (fr) |
PT (1) | PT1559427E (fr) |
RU (1) | RU2321401C2 (fr) |
SI (1) | SI1559427T1 (fr) |
WO (1) | WO2004041276A1 (fr) |
ZA (1) | ZA200503510B (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10351271A1 (de) * | 2003-10-31 | 2005-06-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz |
DK2216021T3 (da) | 2007-11-02 | 2012-11-05 | Astellas Pharma Inc | Farmaceutisk sammensætning til behandling af overaktiv blære |
EP2223690A4 (fr) * | 2007-12-21 | 2011-02-23 | Astellas Pharma Inc | Composition pharmaceutique utilisée pour atténuer les symptômes du tractus urinaire inférieur |
PE20091825A1 (es) * | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
TWI478712B (zh) * | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
US20110262566A1 (en) * | 2008-11-07 | 2011-10-27 | Dainippon Sumitomo Pharma Co., Ltd. | Novel useful therapeutic agent for lower urinary tract symptom |
US8586760B2 (en) | 2009-06-15 | 2013-11-19 | Auspex Pharmaceuticals, Inc. | Aminothiazole modulators of beta-3-adrenoreceptor |
WO2011122523A1 (fr) * | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | Composition pharmaceutique à libération contrôlée |
PT2554168T (pt) | 2010-03-29 | 2018-02-28 | Astellas Pharma Inc | Composição farmacêutica de libertação controlada |
US9655885B2 (en) | 2011-05-18 | 2017-05-23 | Dr. Reddy's Laboratories Ltd. | Amorphous mirabegron and processes for crystal forms of mirabegron |
WO2012156998A2 (fr) * | 2011-05-18 | 2012-11-22 | Dr. Reddy's Laboratories Limited | Mirabegron amorphe et procédés de préparation de formes cristallines de mirabegron |
US20150031734A1 (en) | 2012-03-30 | 2015-01-29 | Astellas Pharma Inc. | Pharmaceutical composition containing mirabegron |
US20150306090A1 (en) | 2012-08-31 | 2015-10-29 | Astellas Pharma Inc. | Orally administered medical composition |
WO2014132270A2 (fr) * | 2013-02-27 | 2014-09-04 | Msn Laboratories Limited | Procédé de préparation de monochlorydrate d'acétamide 2- (2-aminothiazol -4-yl)-n- [4- (2- {[ (2r) -2-hydroxy -2-phényl-éthyl] amino} éthyl) phényl], de ses intermédiaires et polymorphe de celui-ci |
CN103193730A (zh) * | 2013-04-17 | 2013-07-10 | 苏州永健生物医药有限公司 | 一种米拉贝隆的合成方法 |
CN103193658A (zh) * | 2013-04-18 | 2013-07-10 | 苏州永健生物医药有限公司 | 一种(r)-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法 |
CN103232368B (zh) * | 2013-04-18 | 2015-08-12 | 苏州永健生物医药有限公司 | 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法 |
CN103232352B (zh) * | 2013-05-11 | 2015-12-23 | 苏州永健生物医药有限公司 | (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯 |
MX2016001030A (es) * | 2013-07-23 | 2016-10-07 | Allergan Inc | Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. |
ITMI20131653A1 (it) * | 2013-10-07 | 2015-04-08 | Dipharma Francis Srl | Forme cristalline di un agonista adrenergico |
RU2550968C1 (ru) * | 2013-11-29 | 2015-05-20 | Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации | Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем |
WO2015155664A1 (fr) * | 2014-04-08 | 2015-10-15 | Suven Life Sciences Limited | Procédé amélioré de préparation de 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2-phényléthyl] amino]-éthyl)phényl]acétamide |
WO2015162536A1 (fr) * | 2014-04-22 | 2015-10-29 | Calyx Chemicals And Pharmaceuticals Ltd. | Nouveau procédé de préparation de mirabégron et de son intermédiaire |
CN104016943A (zh) * | 2014-05-23 | 2014-09-03 | 苏州凯瑞医药科技有限公司 | 一种米拉贝隆的合成方法 |
CN104016877B (zh) * | 2014-06-13 | 2017-02-15 | 南京海融制药有限公司 | 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用 |
CN104230840A (zh) * | 2014-09-05 | 2014-12-24 | 安徽联创药物化学有限公司 | 米拉贝隆的合成方法 |
WO2016081772A1 (fr) | 2014-11-20 | 2016-05-26 | Allergan, Inc. | Procédés et compositions comprenant de la desmopressine combinée à un antagoniste du récepteur alpha-adrénergique |
CN104496841B (zh) * | 2014-11-26 | 2017-01-25 | 南京工业大学 | 一种米拉贝隆中间体的合成方法 |
CN104744292A (zh) * | 2015-03-11 | 2015-07-01 | 南京工业大学 | (r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法 |
JP2018090490A (ja) * | 2015-03-31 | 2018-06-14 | アステラス製薬株式会社 | ミラベグロン含有医薬組成物 |
JP6618736B2 (ja) | 2015-09-01 | 2019-12-11 | 沢井製薬株式会社 | ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法 |
CN106278909B (zh) * | 2016-08-12 | 2022-07-15 | 浙江华海药业股份有限公司 | 一种米拉贝隆中间体的后处理方法 |
EP3489224A1 (fr) | 2017-02-14 | 2019-05-29 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Promédicaments mirabegron |
KR102051132B1 (ko) * | 2017-03-17 | 2019-12-02 | 주식회사 종근당 | 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물 |
KR101868438B1 (ko) | 2017-04-13 | 2018-06-20 | (주) 성운파마코피아 | 아미드 유도체의 제조방법 |
US11123320B2 (en) | 2017-05-31 | 2021-09-21 | Sbi Pharmaceuticals, Co., Ltd. | Prophylactic or therapeutic agent for hyperaciive bladder |
KR102398639B1 (ko) | 2017-06-20 | 2022-05-17 | (주) 성운파마코피아 | 아미드 유도체의 염 및 그 제조방법 |
WO2019013583A2 (fr) | 2017-07-14 | 2019-01-17 | 주식회사 대웅제약 | Préparation pharmaceutique et son procédé de préparation |
KR101937713B1 (ko) | 2017-07-14 | 2019-01-14 | 주식회사 대웅제약 | 약제학적 제제 및 그 제조방법 |
KR20200117091A (ko) | 2019-04-02 | 2020-10-14 | 제이투에이치바이오텍 (주) | 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도 |
EP3722285B1 (fr) | 2020-04-08 | 2022-03-30 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Procédé de préparation de mirabegron énacarbile |
CN113816864B (zh) * | 2020-06-18 | 2024-03-29 | 南京正大天晴制药有限公司 | 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法 |
KR20220081033A (ko) | 2020-12-08 | 2022-06-15 | 주식회사 한서켐 | 미라베그론 α형 결정의 제조방법 |
EP4338729A1 (fr) | 2022-09-19 | 2024-03-20 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Comprimé comprenant du mirabegron |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07119189B2 (ja) | 1989-09-28 | 1995-12-20 | 北陸製薬株式会社 | 光学活性なベンジルアルコール誘導体及びその用途 |
GB9107827D0 (en) | 1991-04-12 | 1991-05-29 | Fujisawa Pharmaceutical Co | New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
IL104567A (en) | 1992-02-03 | 1997-03-18 | Fujisawa Pharmaceutical Co | Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
JPH06293664A (ja) | 1993-04-05 | 1994-10-21 | Fujisawa Pharmaceut Co Ltd | β3−アドレナリン作動薬の新規医薬用途 |
AU6581294A (en) | 1993-04-26 | 1994-11-21 | Fujisawa Pharmaceutical Co., Ltd. | Ethanolamine derivatives useful for the treatment of gastrointestinal disorders |
JPH07228543A (ja) | 1994-02-16 | 1995-08-29 | Fujisawa Pharmaceut Co Ltd | β3−アドレナリン作動薬の新規医薬用途 |
EP0940387B1 (fr) | 1995-10-26 | 2003-05-07 | Mitsubishi Pharma Corporation | Composes de phenylethanolamine utiles en tant que beta3 agonistes, leurs procede et intermediaires de production |
EP0932401A1 (fr) * | 1996-07-01 | 1999-08-04 | Sepracor, Inc. | Procedes et compositions de traitement de l'incontinence urinaire par (r, r)-glycopyrrolate enrichi par enantiomere |
KR20000068208A (ko) | 1996-08-19 | 2000-11-25 | 간자와 무츠와 | 빈뇨 및 요실금의 예방·치료제 |
EP1014957A4 (fr) * | 1997-08-28 | 2004-01-28 | Afferon Corp | Therapie contre l'incontinence urinaire |
KR100506568B1 (ko) * | 1997-10-17 | 2006-04-21 | 아스텔라스세이야쿠 가부시키가이샤 | 아미드유도체및이의염,및이를포함하는약제학적제제 |
WO1999031045A1 (fr) * | 1997-12-18 | 1999-06-24 | Kissei Pharmaceutical Co., Ltd. | Derives d'acide phenylaminoalkylcarboxylique et compositions medicamenteuses les contenant |
US6696489B1 (en) * | 1998-04-14 | 2004-02-24 | Kissei Pharmaceutical Co., Ltd. | 2-Methylpropionic acid derivatives and medicinal compositions containing the same |
MY126489A (en) * | 1998-07-08 | 2006-10-31 | Kissei Pharmaceutical | Phenoxyacetic acid derivatives and medicinal compositions containing the same |
EP1218536A2 (fr) * | 1999-02-12 | 2002-07-03 | Genset | Marqueurs bialleles derives de regions genomiques porteuses de genes intervenant dans le metabolisme de l'acide arachidonique |
GB2356197A (en) * | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
JP2001114736A (ja) * | 1999-10-19 | 2001-04-24 | Kissei Pharmaceut Co Ltd | 2−アミノプロパノール誘導体 |
EP1258253A1 (fr) | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Nouveaux remedes et utilisation d'un agoniste beta3 |
AUPQ585000A0 (en) * | 2000-02-28 | 2000-03-16 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
AR035605A1 (es) * | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
US7342117B2 (en) | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
WO2006102029A2 (fr) | 2005-03-21 | 2006-09-28 | Dov Pharmaceutical, Inc. | Methodes et compositions destinees au traitement de l'incontinence urinaire |
-
2003
- 2003-11-04 US US10/534,290 patent/US7750029B2/en not_active Ceased
- 2003-11-04 BR BR0316080-7A patent/BR0316080A/pt not_active Application Discontinuation
- 2003-11-04 KR KR1020057008158A patent/KR100967070B1/ko active IP Right Review Request
- 2003-11-04 AU AU2003284700A patent/AU2003284700B2/en not_active Expired
- 2003-11-04 EP EP03770134A patent/EP1559427B1/fr not_active Expired - Lifetime
- 2003-11-04 NZ NZ539577A patent/NZ539577A/en not_active IP Right Cessation
- 2003-11-04 DK DK03770134.9T patent/DK1559427T3/da active
- 2003-11-04 US US10/534,290 patent/US20060115540A1/en active Granted
- 2003-11-04 MX MXPA05004925A patent/MXPA05004925A/es active IP Right Grant
- 2003-11-04 PT PT03770134T patent/PT1559427E/pt unknown
- 2003-11-04 ZA ZA200503510A patent/ZA200503510B/en unknown
- 2003-11-04 CN CNB2003801028894A patent/CN100406011C/zh not_active Expired - Lifetime
- 2003-11-04 SI SI200331996T patent/SI1559427T1/sl unknown
- 2003-11-04 PL PL376771A patent/PL211687B1/pl unknown
- 2003-11-04 JP JP2004549600A patent/JP3815496B2/ja not_active Expired - Lifetime
- 2003-11-04 US US13/542,308 patent/USRE44872E1/en not_active Expired - Lifetime
- 2003-11-04 RU RU2005117367/15A patent/RU2321401C2/ru active
- 2003-11-04 WO PCT/JP2003/014065 patent/WO2004041276A1/fr active Application Filing
- 2003-11-04 CA CA2503570A patent/CA2503570C/fr not_active Expired - Lifetime
- 2003-11-04 ES ES03770134T patent/ES2360353T3/es not_active Expired - Lifetime
- 2003-11-04 AT AT03770134T patent/ATE500827T1/de active
- 2003-11-04 DE DE60336334T patent/DE60336334D1/de not_active Expired - Lifetime
-
2005
- 2005-04-19 IL IL168121A patent/IL168121A/en active IP Right Grant
- 2005-06-06 NO NO20052691A patent/NO334948B1/no not_active IP Right Cessation
-
2008
- 2008-12-12 US US12/333,357 patent/US20090093529A1/en not_active Abandoned
-
2011
- 2011-04-18 CY CY20111100395T patent/CY1111399T1/el unknown
- 2011-05-27 US US13/117,638 patent/US8835474B2/en not_active Expired - Lifetime
-
2013
- 2013-06-17 LU LU92218C patent/LU92218I2/fr unknown
- 2013-06-19 FR FR13C0032C patent/FR13C0032I2/fr active Active
- 2013-06-19 HU HUS1300027C patent/HUS1300027I1/hu unknown
- 2013-06-19 CY CY2013023C patent/CY2013023I1/el unknown
- 2013-06-20 NL NL300599C patent/NL300599I2/nl unknown
- 2013-06-20 BE BE2013C040C patent/BE2013C040I2/fr unknown
-
2015
- 2015-01-19 NO NO2015001C patent/NO2015001I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU92218I2 (fr) | Mirabegron ou un de ses sels | |
LU92433I2 (fr) | Olodatérol, ses isomères optiques individuels, mélanges d'énantiomères individuels ou de racémates, ses sels d'addition d'acide avec des acides pharmaceutiquement acceptables, ainsi que ses solvates et/ou ses hydrates, en particulier l'olodatérol et le chlorhydrate d'olodatérol | |
EA200100826A1 (ru) | 16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике | |
LU90426I2 (fr) | Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir | |
GB0318438D0 (en) | Early entry | |
RS50534B (sr) | Intranazalna formulacija rotigotina | |
WO2002085861A8 (fr) | Composes d'imidazolidine et leur utilisation comme antagonistes de cxcr3 | |
CY1108480T1 (el) | Ανταγωνιστες κιμ-1 και χρηση για την τροποποιηση του ανοσιακου συστηματος | |
DE60131041D1 (de) | Implantierbare Herzvorrichtung zur Überwachung der Verschlechterung oder Verbesserung von Herzerkrankungen | |
ITMI20041890A1 (it) | Metodo per la compensazione della deriva in misure radar con l'ausilio di segnali radar di riferimento | |
Romer | Pharmacological evaluation of mild analgesics. | |
ITMI20022394A1 (it) | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. | |
SE9301923D0 (sv) | Reinforcing device for bathtub | |
ITMI20041954A1 (it) | "procedimento per stimare lapendenza longitudinale del piano stradale" | |
FR2835921B1 (fr) | Utilisation d'une sonde capacitive pour determiner la biomasse de bacteries lactiques | |
ES531572A0 (es) | Procedimiento de preparacion de polimetileno iminas disustituidas | |
FR2844701B1 (fr) | Materiel d'osteosynthese pour os longs, notamment pour l'osteosynthese d'un radius ou d'un cubitus | |
CY1105789T1 (el) | Νεα μεθοδος για τη συνθεση πepιντοπριλ και των φαρμακευτικως αποδεκτων αλατων αυτου | |
ATE349459T1 (de) | Polymorph b eines bekannten thiophencarbonsäuredodecahydrocyclopenta(a)phen ntrenylesters | |
HUP0002727A2 (hu) | Eljárás fibrinogén csökkentésére benzotiofénszármazékok felhasználásával | |
EA200000168A1 (ru) | Фармацевтическая композиция, снижающая продуцирование белка мср-1 | |
FR2799212B1 (fr) | Appareil de traitement electrochimique de la surface interne d'alesages | |
IT1317858B1 (it) | Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione | |
RU2004105132A (ru) | Способ определения показаний к противорецидивному лечению больных псориазом | |
ITMI950303A0 (it) | Componente integrato particolarmente per impedire la formazione di un transistor parassita |